glp 1 agonist new Frontiers Glucometabolic outcomes of GLP-1 receptor
Description
The $150 monthly difference ($1,800 annually) is significant but not as prohibitive as the brand-name cost difference
The company plans to present a more detailed analysis of the MOMENTUM trial data at a TBD scientific conference
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
The follow-up substance, semaglutide, has been developed into Ozempic as a diabetes treatment and Wegovy as an obesity treatment
